Management of Posttransplantation Diabetes Mellitus (PTDM).
10.4285/jkstn.2011.25.1.8
- Author:
Bong Soo CHA
1
;
Jae Hoon MOON
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. bscha@yuhs.ac
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Organ transplantation;
Risk factors;
Postoperative complications;
Diagnosis;
Treatment outcome
- MeSH:
Adrenal Cortex Hormones;
Calcineurin;
Diabetes Mellitus;
Hepacivirus;
Humans;
Immunosuppressive Agents;
Obesity;
Organ Transplantation;
Postoperative Complications;
Risk Factors;
Transplants;
Treatment Outcome
- From:The Journal of the Korean Society for Transplantation
2011;25(1):8-14
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
New-onset diabetes after transplantation (NODAT) is a common complication of solid-organ transplantation. As long-term posttransplant survival continues to improve, increasing attention has been placed on NODAT. Because NODAT is a potent predictor of graft failure and cardiovascular mortality in the transplant population, early detection and management of NODAT are important issues. The risk factors for NODAT in transplant recipients include older age, obesity, family history, hepatitis C virus infection, and immunosuppressive agents, such as corticosteroids and calcineurin inhibitors. Management of NODAT must be considered at the pretransplantation stage to screen high risk patients and prevent NODAT. Although NODAT management is similar to type 2 diabetes management in the general population, there are some specific considerations in NODAT management, including the immunosuppressive agent. Further studies are needed to suggest optimal management guidelines for NODAT.
